An agreement between EDX Medical Group and Thermo Fisher Scientific EMEA Ltd, a world leader in supplying life sciences solutions and services, will enable both companies to jointly develop and potentially commercialise a number of clinical-grade assays – including novel and innovative cancer diagnostic solutions
This multi project collaboration will harness Thermo Fisher’s powerful technologies and information translation systems to deliver a number of advanced testing solutions in development at EDX or licensed from partners, including a proprietary assay to enable personalised radiotherapy and a novel chemotherapy toxicity assay focusing on serious adverse events.
Thermo Fisher Scientific EMEA Ltd is part of Thermo Fisher Scientific Inc. (NYSE: TMO) which is the world leader in serving science, with annual revenue over $40 billion. The company’s mission is to enable customers to make the world healthier, cleaner and safer. Thermo Fisher delivers an unrivalled combination of innovative technologies, purchasing convenience and pharmaceutical services through its industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
